Measuring Metabolism in Tumor Spheroids
The geometry decides the biology
Oxygen diffuses roughly 100–200 µm into tissue before being consumed. A spheroid of 400 µm diameter therefore has an outer proliferating rim, an intermediate quiescent zone, and a core that is hypoxic or necrotic.
| Diameter | Composition | What a bulk measurement reports |
|---|---|---|
| < 200 µm | Mostly normoxic, proliferating | A reasonable approximation of a cell |
| 200–400 µm | Rim plus hypoxic core | An average of two populations |
| > 500 µm | Rim, quiescent zone, necrotic core | An average that is dominated by dead cells |
Important distinction. A spheroid "metabolic phenotype" measured at day 10 is a different object from the same line measured at day 3. Growth day is a variable with a larger effect than most treatments, and it is frequently unreported.
Size control
| Approach | Method | Consequence |
|---|---|---|
| Seeding density | Fixed cell number per well, non-adhesive plate | Standard; size still varies |
| Filtration | Force through a mesh | Narrow distribution; shear stress |
| Hanging drop | Fixed volume per drop | Very uniform; low throughput |
| Microfluidic trapping | Physical confinement | Uniform; specialised equipment |
| Centrifugation | Pellet formation | Fast; density gradients |
Whatever the method, the distribution should be reported, not a mean. A culture with a mean of 400 µm and a range of 200–700 µm contains three different tissues.
What can be measured, and how
| Measurement | Method | Limitation |
|---|---|---|
| Oxygen consumption | Extracellular flux with spheroid embedding | Diffusion within the plate; edge effects |
| Glycolysis | Lactate accumulation in conditioned medium | Includes core-derived lactate |
| Metabolite pools | Bulk mass spectrometry after dissociation | Dissociation changes pools within minutes |
| Labelled flux | ¹³C on pooled spheroids | Requires many spheroids; average over zones |
| Per-zone analysis | Sectioning, or spatial methods | Low throughput; preserves architecture |
| Viability gradients | Live/dead staining with confocal | Penetration of the dye itself |
Readout note. For extracellular flux on intact spheroids, the measured rate is limited by diffusion from the core to the sensor as well as by metabolism. Two spheroids of the same size but different density will differ in apparent flux because of diffusion, not biology. This can be partially controlled by comparing size-matched spheroids and by using a cell-number-matched 2D control.
Lactate and glucose in conditioned medium
Spheroid medium measurements are the most accessible and the most misinterpreted.
| Quantity | What it reports | Confounder |
|---|---|---|
| Glucose depletion | Net consumption by the whole spheroid | Core cells may be consuming nothing |
| Lactate accumulation | Net release | Core may be re-consuming lactate |
| Lactate/glucose ratio | Net exchange ratio | Not per-cell; not per-zone |
| Ammonia | Glutaminolysis | Medium degradation contributes |
The last point in the third row is the key one: in a spheroid with a hypoxic core, lactate produced at the rim can be oxidised in the core, so the net release understates production. The ratio is a net balance, not a rate.
Dissociation or not
| Approach | Preserves | Loses |
|---|---|---|
| Intact spheroid | Architecture, gradients | Per-cell attribution |
| Enzymatic dissociation | Per-cell analysis by flow | Gradients; stress signature within minutes |
| Sectioning | Spatial information | Throughput; z-axis sampling |
| Outgrowth | Migratory and proliferative capacity | The original organisation |
Caveat on dissociation. Dissociation induces immediate-early genes and heat shock responses within minutes, and the hypoxic core cells are the most fragile. A single-cell profile of a dissociated spheroid is biased toward the cells that survived dissociation, which are the rim cells — exactly the population that was already over-represented.
What a spheroid can and cannot support
| Claim | Supportable | Why |
|---|---|---|
| Nutrient gradient exists | Yes | Measured by reporters or sectioning |
| Cells at the core are hypoxic | Yes | With a validated reporter and size control |
| The population shifts to glycolysis | Partly | Net exchange; not per-zone |
| Drug penetrates poorly | Yes | With imaging or a penetration assay |
| This is a model of the tumour microenvironment | Partly | No vasculature, no immune cells, no stroma |
| This recapitulates patient heterogeneity | Rarely | Clonal selection in culture |
Important distinction. A spheroid adds geometry and gradients. It does not add vasculature, immune cells, fibroblasts or systemic supply. The word "microenvironment" in a spheroid paper usually means "gradient", and the claim should say which features are present.
Practical parameters
| Parameter | Typical value | Note |
|---|---|---|
| Seeding density | 500–2,000 cells per well (96-well, round-bottom, ultra-low attachment) | Line-dependent |
| Medium change | Every 2–3 days, half-volume | Avoid disturbing the spheroid |
| Size at assay | 300–500 µm | Beyond that, the necrotic fraction dominates |
| Spheroids per condition | ≥ 8–12 | Size heterogeneity is the variance source |
| Equilibration for flux | 1 h in assay buffer | Diffusion equilibrium is slower than in 2D |
Failures that recur
- • Size unreported. The single largest confounder.
- • Mean diameter reported without a distribution.
- • Day 10 spheroids used as "3D culture" without acknowledging the necrotic core.
- • Lactate release reported as production. The core re-consumes it.
- • Dissociated cells profiled and called "spheroid cells". The rim is over-represented.
- • 2D control not matched for cell number, so the comparison is between different amounts of tissue.
- • "Tumour microenvironment" claimed without stroma or immune cells.
Where this connects
- • Tumour metabolic dependency article supplies the environment argument: dependency measured in 2D may not exist in a gradient.
- • Mitochondrial pillar supplies the oxygen and HIF logic that the gradient imposes.
- • Disease pillar supplies the model-tier framing: a spheroid sits between a line and an animal, and supports a specific subset of claims.
Scientific interpretation and experimental design
- • Report size distribution and day.
- • Match sizes across conditions.
- • Match cell number against the 2D control.
- • Treat net exchange as a balance, not a rate.
- • Do not dissociate and call it representative. The rim survives.
- • Name the features the model actually has. Gradient, not microenvironment.
- • Use per-zone methods when the claim is about zones.
Selected references for further reading
- • Hirschhaeuser F, et al. Multicellular tumor spheroids: an underestimated tool is catching up again. Journal of Biotechnology. 2010;148:3–15.
- • Riffle S, Hegde RS. Modeling tumor cell adaptations to hypoxia in multicellular tumor spheroids. Journal of Experimental & Clinical Cancer Research. 2017;36:102.
- • Friedrich J, Seidel C, Ebner R, Kunz-Schughart LA. Spheroid-based drug screen: considerations and practical approach. Nature Protocols. 2009;4:309–324.
- • Place TL, Domann FE, Case AJ. Limitations of oxygen delivery to cells in culture: an underappreciated problem in basic and translational research. Free Radical Biology and Medicine. 2017;113:311–322.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PBRM1 Knockout A-549 Cell Line | EDJ0001-K01 | Human | 55193 | Details Get a Quote |
| YTHDC1 Knockout A-549 Cell Line | EDC07652 | Human | 91746 | Details Get a Quote |
| TP53 Knockout HCT 116 Cell Line | EDC07854 | Human | 7157 | Details Get a Quote |
| Sirt2 Knockout MH-S Cell Line | EDJ-KQ78173 | Mouse | 64383 | Details Get a Quote |
| TFE3 Knockout KGN Cell Line | EDJ-KQ48 | Human | 7030 | Details Get a Quote |
| Stub1 Knockout MB49 Cell Line | EDJ-KQ53 | Mouse | 56424 | Details Get a Quote |
| ARID1A Knockout SNK-6 Cell Line | EDJ-KQ64 | Human | 8289 | Details Get a Quote |
| Tet1 Knockout Kupffer Cell Line | EDJ-KQ88 | Mouse | 52463 | Details Get a Quote |
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| NR1H2 Knockout HEK293T Cell Line | EDJ-KQ110 | Human | 7376 | Details Get a Quote |
| RPS6KB2 Knockout HEK293 Cell Line | EDJ-KQ125 | Human | 6199 | Details Get a Quote |
| SMAD6 Knockout HEK293 Cell Line | EDJ-KQ126 | Human | 4091 | Details Get a Quote |
| JUN Knockout HEK293 Cell Line | EDJ-KQ176 | Human | 3725 | Details Get a Quote |
| JUN Knockout HEK293T Cell Line | EDJ-KQ184 | Human | 3725 | Details Get a Quote |
| ALKBH5 Knockout HEK293 Cell Line | EDJ-KQ186 | Human | 54890 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »